Filtered By:
Condition: Migraine
Cancer: Cancer
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 47 results found since Jan 2013.

E-025 The rate and predictors of 30-day readmission in patients treated for cerebral aneurysms: a large single-center study
ConclusionIn our study, risk factors for 30-day readmission were increasing BMI, cancer, increasing aneurysm width, and anticoagulation use. Future studies should focus on aneurysm dimensions and the use of blood thinners as the literature pertaining these predictors is still scarce.Abstract E-025 Table 1 Variables N(%) 30-day Readmission 36 (6.6) Cause of Readmission: Infection Stroke Re-Rupture Wound Dehiscence Seizures CSF Leak Hydrocephalus Headache Wound Area Swelling Groin Hematoma Pseudo meningocele 9 (25)11 (30.6)1 (2.8)1 (2.8)1 (2.8)1 (2.8)1 (2.8)7 (19.4)2 (5.6)1 (2.8)1 (2.8) Causes and Rate of ReadmissionAbstrac...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: El Naamani, K., Hunt, A., Jain, P., Lawall, C., Yudkoff, C., El Fadel, O., Ghanem, M., Momin, A., Atallah, E., Abbas, R., Zakar, R., Tjoumakaris, S., Gooch, M., Herial, N., Zarzour, H., Schmidt, R., Rosenwasser, R., Jabbour, P. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

A Retrospective Observational Study of Neurological Manifestations in COVID-19 (SON-CoV)
Conclusion: CNS symptoms of COVID-19 are more common than PNS symptoms. Stroke is the most frequent (46%) COVID-CNS symptom, which occurs in people of age above 35 years and is associated with high mortality.PMID:37355862 | DOI:10.5005/japi-11001-0107
Source: Journal of the Association of Physicians of India - June 25, 2023 Category: General Medicine Authors: Neetu Ramrakhiani Neeraj Bhutani Deepak Chaudhary Pooja Parab Karni Singh Priya Agrawal Vikas Gupta Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Burden of neurological diseases in Asia from 1990 to 2019: a systematic analysis using the Global Burden of Disease Study data
Conclusions This study demonstrated the burden of neurological diseases in Asia. To reduce the burden of neurological diseases, strategies suitable for each country’s real healthcare needs and challenges are needed; this study can serve as the cornerstone of these strategies.
Source: BMJ Open - September 7, 2022 Category: General Medicine Authors: Kang, S., Eum, S., Chang, Y., Koyanagi, A., Jacob, L., Smith, L., Shin, J. I., Song, T.-J. Tags: Open access, Epidemiology Source Type: research

Why Acupuncture Is Going Mainstream in Medicine
When the opioid addiction crisis began to surge in the U.S. about a decade ago, Dr. Medhat Mikhael spent a lot of time talking to his patients about other ways to heal pain besides opioids, from other types of medications to alternative treatments. As a pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, Calif., he didn’t anticipate leaving behind the short-term use of opioids altogether, since they work so well for post-surgical pain. But he wanted to recommend a remedy that was safer and still effective. That turned out to be acupuncture. “Like any treatment, acupuncture...
Source: TIME: Health - April 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate medicine Source Type: news

Widely used anti-nausea drugs raise risk for ischemic stroke, study finds
A class of commonly used drugs designed to relieve nausea and vomiting caused by migraine, cancer treatment or surgery has been linked with an increased risk for ischemic stroke, a study published by the BMJ found.
Source: Health News - UPI.com - March 23, 2022 Category: Consumer Health News Source Type: news

Migraine and Medical Ramifications: A Comprehensive Overview Based on Observational Study Meta-Analyses
Conclusion: The results showed that migraine increased the risk of 29 health outcomes, though lowered the risk of breast cancer. However, evidence quality was graded as high only for angina. The evidence quality of ischaemic stroke, stroke, MACCE, WMAs, and asthma was graded as moderate. All remaining 24 outcomes had an evidence grade of “weak.”
Source: Frontiers in Neurology - December 24, 2021 Category: Neurology Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The trend analysis of neurological disorders as major causes of death and disability according to human development, 1990-2019
This study aims to assess the trends in the incidence rate of neurological disorders in developed and developing countries worldwide during 1990-2019. The age-standardized incidence rate (per 100000 persons) of neurological disorders was the primary outcome, extracted from the Global Burden of Disease database for 189 countries and territories from 1990 to 2019. Using the Human Development Index (HDI), countries were classified into developed (HDI ≥ 0.7) and developing (HDI < 0.7) groups. Longitudinal analysis was performed using the Latent Growth Model (LGM) to assess the change in the incidence rate of neurological ...
Source: Environmental Science and Pollution Research International - October 5, 2021 Category: Environmental Health Authors: Nasrin Borumandnia Hamid Alavi Majd Hassan Doosti Keyvan Olazadeh Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019
ConclusionsThe increase in YLDs associated with neurological conditions is mostly due to population ageing and growth: nevertheless, lived disability and, as a consequence, impact on health systems has increased. Actions are needed to improve outcome and mitigate disability associated with neurological conditions, spanning among diagnosis, treatment, care pathways and workplace interventions.
Source: Journal of Neurology - September 8, 2021 Category: Neurology Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The severity of vasomotor symptoms and number of menopausal symptoms in postmenopausal women and select clinical health outcomes in the Women's Health Initiative Calcium and Vitamin D randomized clinical trial
This study evaluated whether vasomotor symptom (VMS) severity and number of moderate/severe menopausal symptoms (nMS) were associated with health outcomes, and whether calcium and vitamin D (CaD) modified the risks. Methods: The Women's Health Initiative CaD study was a double blind, randomized, placebo-controlled trial, which tested 400 IU of 25-hydroxyvitamin-D and 1,000 mg of calcium per day in women aged 50 to 79 years. This study included 20,050 women (median follow-up of 7 y). The outcomes included hip fracture, colorectal cancer, invasive breast cancer, all-cause mortality, coronary heart disease, stroke, cardi...
Source: Menopause - October 30, 2020 Category: OBGYN Tags: Original Studies Source Type: research

Transcutaneous Electrical Nerve Stimulation in Relieving Neuropathic Pain: Basic Mechanisms and Clinical Applications
AbstractPurpose of ReviewTranscutaneous electrical nerve stimulation (TENS) is widely used as a non-pharmacological approach for pain relief in a variety of clinical conditions. This manuscript aimed to review the basic mechanisms and clinical applications regarding the use of TENS for alleviating the peripheral (PNP) and central neuropathic pain (CNP).Recent FindingsBasic studies on animal models showed that TENS could alleviate pain by modulating neurotransmitters and receptors in the stimulation site and its upper levels, including the spinal cord, brainstem, and brain. Besides, many clinical studies have investigated t...
Source: Current Pain and Headache Reports - February 17, 2020 Category: Neurology Source Type: research